Natus Medical to acquire global Camino® ICP monitoring product line, U.S. rights to Integra’s fixed pressure shunts, and U.S. rights to Codman’s DURAFORM®, EVD catheters and CSF collection systems
Integra is providing a preliminary estimate for a fourth quarter 2017 revenue contribution of approximately $60 million to $65 million from the Codman Neurosurgery acquisition net of divestitures, assuming an October 2017 close
PLAINSBORO, N.J., Sept 12 (Bernama-GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a global leader in medical technology, today announced that it has signed a definitive agreement to sell certain neurosurgery assets to Natus Medical for $47.5 million. The divestiture is contingent on the consummation of Integra’s proposed acquisition of Codman Neurosurgery from Johnson & Johnson.
http://mrem.bernama.com/viewsm.php?idm=30016
No comments:
Post a Comment